Clinical Trial Update: Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of magrolimab in combination with azacitidine and venetoclax for acute myeloid leukemia has been terminated, with results posted on 2026-04-23.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Magrolimab (magrolimab)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-04-23